Slingshot Insights | Hrtx Overview

HRTX Overview

Upcoming Projects (HRTX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (HRTX)

A Third Look: Discussing the post-surgical setting following orthopedic and soft tissue procedures along with Zynrelef's recent label expansion (January 2024) which will now cover an estimated 13 million procedures annually
Ticker: HRTX
Executed On: Feb 26, 2024 at 09:00 AM EST
A Second Look: Discussing the post-surgical setting following orthopedic and soft tissue procedures along with Zynrelef's recent label expansion (January 2024) which will now cover an estimated 13 million procedures annually
Ticker: HRTX
Executed On: Feb 14, 2024 at 11:00 AM EST
Discussing the post-surgical setting following orthopedic and soft tissue procedures along with Zynrelef's recent label expansion (January 2024) which will now cover an estimated 13 million procedures annually
Ticker: HRTX
Executed On: Feb 13, 2024 at 08:30 AM EST
A Fourth View: Discussing the recent FDA approval of Heron Therapeutics' Aponvie (aprepitant) - NK1 inhibitor IV infusion - and how if fits into the treatment landscape of Postoperative nausea and vomiting (PONV)
Ticker: HRTX
Executed On: Oct 31, 2022 at 01:00 PM EDT
A Third View: Discussing the recent FDA approval of Heron Therapeutics' Aponvie (aprepitant) - NK1 inhibitor IV infusion - and how if fits into the treatment landscape of Postoperative nausea and vomiting (PONV)
Ticker: HRTX
Executed On: Sep 26, 2022 at 11:00 AM EDT
A Second View: Discussing the recent FDA approval of Heron Therapeutics' Aponvie (aprepitant) - NK1 inhibitor IV infusion - and how if fits into the treatment landscape of Postoperative nausea and vomiting (PONV)
Ticker: HRTX
Executed On: Sep 21, 2022 at 05:00 PM EDT
Discussing the recent FDA approval of Heron Therapeutics' Aponvie (aprepitant) - NK1 inhibitor IV infusion - and how if fits into the treatment landscape of Postoperative nausea and vomiting (PONV)
Ticker: HRTX
Executed On: Sep 20, 2022 at 02:00 PM EDT
A third look at the potential use of VX-548 in treating patients with acute and neuropathic pain
Tickers: VRTX, HRTX
Executed On: Sep 08, 2022 at 11:00 AM EDT
A Second View: Discussing the Launch of Zynrelef, following its approval in May 2021 as post-surgical analgesia and it's recent label expansion (December 2021)
Ticker: HRTX
Executed On: Apr 21, 2022 at 09:00 AM EDT
Discussing the Launch of Zynrelef, following its approval in May 2021 as post-surgical analgesia and it's recent label expansion (December 2021)
Ticker: HRTX
Executed On: Apr 18, 2022 at 04:00 PM EDT

Upcoming & Overdue Catalysts (HRTX)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (HRTX)

Don’t see a strategic initiative related to the company you care about? Create your own!